References: 1p36 Deletion, Candidate Genes, CHD5, Clinical Significance
  1. Fong CT, Dracopoli NC, White PS, Merrill PT, Griffith RC, Housman DE, Brodeur GM: Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: Correlation with N-myc amplification. Proc Natl Acad Sci USA 86: 3753-3757, 1989. PMID: 2566996
  2. White PS, Maris JM, Beltinger C, Sulman E, Marshall HN, Fujimori M, Kaufman BA, Biegel JA, Allen C, Hilliard C, Valentine MB, Look AT, Enomoto H, Sakiyama S, Brodeur GM: A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci USA, USA 92:5520-5524, 1995. PMID: 7777541
  3. Beltinger CP, White PS, Maris JM, Sulman EP, Jensen SJ, LePaslier D, Stallard BJ, Goeddel DV, de Sauvage FJ, Brodeur GM: Physical mapping and genomic structure of the human TNFR2 gene. Genomics 35: 94-100, 1996. PMID: 8661109
  4. Maris JM, Sulman EP, Jensen SJ, Beltinger CP, Allen C, Biegel JA, Brodeur GM, White PS: Cloning, chromosomal localization, physical mapping and genomic characterization of HKR3: a candidate neuroblastoma tumor suppressor gene. Genomics 35: 289-298, 1996. PMID: 8661141
  5. Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS, Hogarty MD, Sulman EP, Thompson PM, Lukens JN, Matthay KK, Seeger RC, Brodeur GM: Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: A Children’s Cancer Group study. J Clin Oncol 18: 1888-1899, 2000. PMID: 10784629
  6. Hogarty MD, Liu X, Guo C. Thompson PM, Weiss MJ, White PS, Sulman EP, Brodeur GM, Maris JM: Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. Med Pediatr Oncol 35: 512-515, 2000. PMID: 11107105
  7. Hogarty MD, Maris JM, White PS, Guo C, Brodeur, GM: Analysis of genomic imprinting at 1p35-36 in neuroblastoma. Med Ped Oncol 36: 52-55, 2001. PMID: 11464906
  8. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS: Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Cancer Res 61:679-86, 2001. PMID: 11212268
  9. Thompson PM, Gotoh T, Kok M, White PS, and Brodeur GM: CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 22:1002-1011, 2003. PMID: 12592387
  10. Brodeur, G.M. Neuroblastoma: biological insights into a clinical enigma. Nature Rev–Cancer 3:203-216, 2003. PMID: 12612655
  11. White PS, Thompson PM, Gotoh T, Okawa ER, Igarashi J, Kok M, Winter C, Gregory SG, Hogarty MD, Maris JM, Brodeur GM: Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 24: 2684-94, 2005. PMID: 15829979
  12. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, Brodeur GM, Cohn SL, Matthay KK, Maris JM; COG. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353: 2243-2253, June 15, 2005. PMID: 16306521
  13. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, Seiser E, Jagannathan J, Shusterman S, Bansal M, Khazi D, Winter C, Okawa E, Grant G, Cnaan A, Zhao H, Cheung NK, Gerald W, London W, Matthay KK, Brodeur GM, Maris JM. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 2006 Jun 15;66(12):6050-62. PMID: 16778177
  14. Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, Brodeur GM, Maris JM: A functional screen identifies miR-34a as a Candidate Neuroblastoma Suppressor Gene. Mol Cancer Res 6(5): 735-742, May 2008. PMID: 18505919
  15. Okawa ER, Gotoh T, Manne, J, Igarashi J, Fujita T, Silverman KA, Xhao, H, Mosse YP, White PS, Brodeur GM. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 27(6) 803-810, Jan 31, 2008. PMID: 17667943
  16. Fujita T, Igarashi J, Okawa ER, Gotoh T. Manne J. Kolla V, Kim J. Zhao H, Pawel BR, London WB, Maris JM, White PS, Brodeur GM: CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 100(13): 940-949, July 2, 2008. PMID: 18577749
References: Role of Receptor Tyrosine Kinases in Neuroblastoma Pathogenesis
  1. Nakagawara A, Arima M, Azar CG, Scavarda NJ, and Brodeur GM. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 52: 1364-1368, 1992. PMID: 1737399
  2. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM: Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. New Engl J Med 328: 847-854, 1993. PMID: 8441429
  3. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM: Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 14: 759-767, 1994. PMID: 7972209
  4. Nakagawara A, Liu X-G, Ikegaki N, White PS, Yamashiro DJ, Nycum LM, Biegel JA, Brodeur GM: Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2). Genomics 25:538-546, 1995. PMID: 7789988
  5. Yamashiro DJ, Nakagawara A, Ikegaki N, Liu X-G, Brodeur GM: Expression of TrkC in human neuroblastoma. Oncogene 12:37-41, 1996. PMID: 8552397
  6. Evans AE, Kisselbach KD, Yamashiro DJ, Ikegaki N, Camoratto AM, Dionne CA, Brodeur GM: Antitumor activity of CEP-751 (KT6587) on human neuroblastoma and medulloblastoma xenografts. Clin Cancer Res 5: 3594-3602, 1999. PMID: 10589776
  7. Eggert A, Ikegaki N, Liu X, Chou TT, Lee VM, Trojanowski JQ, Brodeur GM: Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells. Oncogene 19: 2043-2051, 2000. PMID: 10803465
  8. Eggert A, Grotzer MA, Ikegaki N, Liu XG, Evans AE, and Brodeur GM: Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res 62:1802-1808, 2002. PMID: 11912158
  9. Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE, and Brodeur GM: Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 62:6462-6466, 2002. PMID: 12438236
  10. Schulte JH, Schramm A, Klein-Hitpass L, Klenk M, Wessels H, Hauffa BP, Eils J, Eils R, Brodeur GM, Schweigerer L, Havers W, Eggert A: Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas. Oncogene 24:165-77, 2005. PMID: 15637590
  11. Ho R, Minturn JE, Hishiki T, Zhao H, Wang Q, Cnaan A, Maris J, Evans AE, Brodeur GM: Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res 65: 9868-9875, 2005. PMID: 16267010
  12. Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Petri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H. Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM: Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455(7215): 930-935, Oct 16, 2008. PMID: 18724359
  13. Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, Light JE, Kolla V, Evans AE. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res. 2009 May 15;15(10):3244-50. Epub 2009 May 5. Review. PMID: 19417027
  14. Iyer R, Evans AE, Qi X, Ho R, Minturn JE, Zhao H, Balamuth N, Maris JM, Brodeur GM: Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. Clin Cancer Res 16:1478-1485, 2010. PMID: 20179224
  15. Ho R, Minturn JE, Simpson AM, Iyer R, Light JE, Evans AE, Brodeur GM. The effect of P75 on Trk receptors in neuroblastomas. Cancer Lett. 2011 Mar 17. PMID: 21419569
  16. Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, Groshen S, Hellriegel ET, Bensen-Kennedy D, Matthay KK, Brodeur GM, Maris JM. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol. 2011 (in press). PMID: 21340605